nach oben

Erschienen in:

01.04.2012 | Clinical Study - Patient Study

Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography

verfasst von: Hideyuki Arita, Manabu Kinoshita, Yoshiko Okita, Ryuichi Hirayama, Tadashi Watabe, Kayako Ishohashi, Noriyuki Kijima, Naoki Kagawa, Yasunori Fujimoto, Haruhiko Kishima, Eku Shimosegawa, Jun Hatazawa, Naoya Hashimoto, Toshiki Yoshimine

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The clinical course of meningioma varies from case to case, despite similar characteristics on magnetic resonance (MR) imaging. Functional imaging including ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) has been widely studied for noninvasive preoperative evaluation of brain tumors. However, few reports have examined correlations between meningiomas and findings on ¹¹C-methionine and FDG PET. The objective of this study was to clarify the relationship between tumor characteristics and ¹¹C-methionine and FDG uptake in meningiomas. For 68 meningiomas in 51 cases, ¹¹C-methionine uptake was evaluated by measuring both mean and maximum tumor/normal (T/N) ratio for the whole area of the tumors. FDG uptake in 44 of those meningiomas was also analyzed. Tumor size was measured volumetrically, and tumor-doubling time was estimated. Histopathological evaluation was performed in 19 surgical cases. Mean and maximum T/N ratios of ¹¹C-methionine PET were significantly higher in skull-base lesions than in non-skull-base lesions. Correlations of mean and maximum T/N ratio of ¹¹C-methionine PET with tumor-doubling time, MIB-1 labeling index, microvessel density and World Health Organization grading were not significant. Mean T/N ratio of ¹¹C-methionine PET correlated significantly with tumor volume according to logarithm regression modeling (P < 0.0001, R = 0.544). However, mean and maximum T/N ratio of FDG-PET correlated with none of the tumor characteristics described above. These results suggest that ¹¹C-methionine uptake correlates with tumor volume, but not with tumor aggressiveness.

Hashiba T, Hashimoto N, Izumoto S, Suzuki T, Kagawa N, Maruno M, Kato A, Yoshimine T (2009) Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg 110:675–684PubMedCrossRef

Nakasu S, Fukami T, Nakajima M, Watanabe K, Ichikawa M, Matsuda M (2005) Growth pattern changes of meningiomas: long-term analysis. Neurosurgery 56:946–955 discussion 946-955PubMed

Kallio M, Sankila R, Hakulinen T, Jaaskelainen J (1992) Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 31:2–12PubMedCrossRef

Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT (2011) Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 117:1272–1278PubMedCrossRef

Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J (1999) Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg 90:455–462PubMedCrossRef

Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, Lee MC, Lee DS (2009) 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging 36:1574–1582PubMedCrossRef

De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S (2001) Positron-emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746–750PubMedCrossRef

Kaminogo M, Ishimaru H, Morikawa M, Ochi M, Ushijima R, Tani M, Matsuo Y, Kawakubo J, Shibata S (2001) Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 43:353–363PubMedCrossRef

Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998PubMed

10.

Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237PubMedCrossRef

11.

Buhl R, Nabavi A, Wolff S, Hugo HH, Alfke K, Jansen O, Mehdorn HM (2007) MR spectroscopy in patients with intracranial meningiomas. Neurol Res 29:43–46PubMedCrossRef

12.

Chernov MF, Kasuya H, Nakaya K, Kato K, Ono Y, Yoshida S, Muragaki Y, Suzuki T, Iseki H, Kubo O, Hori T, Okada Y, Takakura K (2011) H-MRS of intracranial meningiomas: what it can add to known clinical and MRI predictors of the histopathological and biological characteristics of the tumor? Clin Neurol Neurosurg 113:202–212PubMedCrossRef

13.

Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ (1987) Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 164:521–526PubMed

14.

Giovacchini G, Fallanca F, Landoni C, Gianolli L, Picozzi P, Attuati L, Terreni M, Picchio M, Messa C, Fazio F (2009) C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med 34:7–10PubMedCrossRef

15.

Lippitz B, Cremerius U, Mayfrank L, Bertalanffy H, Raoofi R, Weis J, Bocking A, Bull U, Gilsbach JM (1996) PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate. Acta Neurochir Suppl 65:108–111PubMed

16.

Shino A, Nakasu S, Matsuda M, Handa J, Morikawa S, Inubushi T (1999) Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. J Neurosurg 91:928–934PubMedCrossRef

17.

Berger G, Maziere M, Knipper R, Prenant C, Comar D (1979) Automated synthesis of 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 30:393–399PubMedCrossRef

18.

Veninga T, Huisman H, van der Maazen RW, Huizenga H (2004) Clinical validation of the normalized mutual information method for registration of CT and MR images in radiotherapy of brain tumors. J Appl Clin Med Phys 5:66–79PubMedCrossRef

19.

Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD (2003) Methyl-[11C]- l-methionine uptake as measured by positron-emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30:868–873PubMedCrossRef

20.

Okita Y, Kinoshita M, Goto T, Kagawa N, Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T (2010) (11)C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. Neuroimage 49:2977–2982PubMedCrossRef

21.

Kuratsu J, Kochi M, Ushio Y (2000) Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 92:766–770PubMedCrossRef

22.

Nakamura M, Roser F, Michel J, Jacobs C, Samii M (2003) The natural history of incidental meningiomas. Neurosurgery 53:62–70 discussion 70-61PubMedCrossRef

23.

Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ (2008) Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol 70:471–477 discussion 477PubMedCrossRef

24.

Iuchi T, Iwadate Y, Namba H, Osato K, Saeki N, Yamaura A, Uchida Y (1999) Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res 21:640–644PubMed

25.

Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, Molls M, Weber WA, Grosu AL (2008) Effect of 11C-methionine-positron-emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys 72:1161–1167PubMedCrossRef

26.

Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, Jeong JM, Lee DS, Jung HW, Lee MC (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:176–182PubMedCrossRef

27.

Ericson K, Lilja A, Bergstrom M, Collins VP, Eriksson L, Ehrin E, von Holst H, Lundqvist H, Langsrom BB, Mosskin M (1985) Positron-emission tomography with ([11C]methyl)-l-methionine, [11C]d-glucose, and [68 Ga] EDTA in supratentorial tumors. J Comput Assist Tomogr 9:683–689PubMedCrossRef

28.

Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, Molls M, Nieder C (2006) 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 66:339–344PubMedCrossRef

29.

Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B (2001) Meningioma treated with interferon-alpha, evaluated with [(11)C]-l-methionine positron-emission tomography. Clin Cancer Res 7:2269–2276PubMed

30.

Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, Petit-Taboue MC, Houtteville JP, Chajari MH, Bouvard G (2000) Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27:778–787PubMedCrossRef

31.

Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, Yoshimura S, Maruyama T, Muragaki Y, Iwama T (2008) Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 29:1176–1182PubMedCrossRef

32.

Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D, Denolin V, Rorive S, Massager N, Baleriaux D, Goldman S (2007) Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 28:455–461PubMed

33.

Principi M, Italiani M, Guiducci A, Aprile I, Muti M, Giulianelli G, Ottaviano P (2003) Perfusion MRI in the evaluation of the relationship between tumour growth, necrosis and angiogenesis in glioblastomas and grade 1 meningiomas. Neuroradiology 45:205–211PubMed

34.

Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332PubMedCrossRef

Titel: Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography
verfasst von: Hideyuki Arita
Manabu Kinoshita
Yoshiko Okita
Ryuichi Hirayama
Tadashi Watabe
Kayako Ishohashi
Noriyuki Kijima
Naoki Kagawa
Yasunori Fujimoto
Haruhiko Kishima
Eku Shimosegawa
Jun Hatazawa
Naoya Hashimoto
Toshiki Yoshimine
Publikationsdatum: 01.04.2012
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0759-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts

Novel cell lines established from pediatric brain tumors

Spinal cord glioneuronal tumor with neuropil-like islands with 1p/19q deletion in an adult with low-grade cerebral oligodendroglioma

Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

Increased tryptophan transport in epileptogenic dysembryoplastic neuroepithelial tumors